. A number of oncogenic and tumoursuppressor gene functions have been demonstrated in squamous cell carcinoma of the head and neck (SCCHN) (Field et al., 1989 (Field et al., , 1991 Field, 1992) To date only two global analyses of the whole genome have been undertaken with the view to determine the fractional allele loss (FAL) of specific tumours and thus provide information concerning the 'genetic burden' of the disease during its progression as measured by clinicopathological parameters and survival data. This type of analysis has been undertaken in colorectal (Vogelstein et al., 1989) and bladder cancers (Knowles et al., 1994) , and provides an indication of interacting genetic mechanisms in the development of these diseases. In addition, the results of such detailed allelotypes may aid the interpretation of carcinogenesis and the development of molecular progression models for specific tumours.
Sinnukry Allelic imbalance or loss of heterozygosity (LOH) studies have been used extensively to identify regions on chromosomes that may contain putative tumour-suppressor genes. We have undertaken an extensive allelotype of 80 specimens of squamous cell carcinoma of the head and neck (SCCHN) using 145 polymorphic microsatellite markers on 39 chromosome arms. Allelic imbalances were found most frequently on chromosome arms 3p, 9p, 17p and 18q with over 45% LOH and imbalances on lp, lq, 2p, Sq, 6p, 6q, 8p. 8q. 9q. lIq, 13q, 17q and 19q were found in more than 20% of SCCHN. These LOH data were analysed against a range of cinicopathological parameters which included previously untreated and previously treated tumours; correlations were found between LOH on 9q and nodes at pathology (P = 0.02) and between histopathological grade and LOH on 12q (P = 0.02) and 13q (P = 0.01). In the group of previously untreated tumours, a correlation was found between site of tumour and LOH on 3p (P = 0.019), and 8p (P = 0.029), while TNM staging correlated with LOH on 3p (P = 0.019) and 17p (P = 0.016). Fractional allele loss (FAL) was calculated for 52 tumours with LOH data on nine or more chromosomal arms and found to have a median value of 0.22 (range 0.0-0.80). Correlations were found between FAL> median value and nodes at pathology (P = 0.01) and tumour grade (P = 0.06), demonstrating that advanced tumours with lymph node metastasis often had LOH at multiple sites. FAL >median value was found to correlate with a poor survival (P<0.03) and, furthermore, FAL>median value correlated with poor survival in the previously untreated patients (P<0.019). These results indicate that assessment of the accumulation of genetic damage. as provided by allelotype data. provides a useful molecular indicator of the tumour behaviour and clinical outcome.
Kevwords: head and neck cancer; oral cancer: allelotype: microsatellites; loss of heterozygosity; fractional allele loss The chromosomal locations of many different putative human tumour-suppressor genes have been identified by loss of heterozygosity (LOH) studies (Rees et al., 1989; Lasko et al., 1991; Latif et al., 1992; Cunningham et al., 1993; Adamson et al., 1994) . A number of oncogenic and tumoursuppressor gene functions have been demonstrated in squamous cell carcinoma of the head and neck (SCCHN) (Field et al., 1989 (Field et al., , 1991 Field, 1992) , and the results of LOH analysis currently point to several novel tumour-suppressor gene sites in this disease (Maestro et al., 1993; Adamson et al., 1994; Ah-See et al., 1994; Field et al., 1994; Kiaris et al., 1994; Li et al., 1994; Loughran et al., 1994; Merlo et al., 1994; Nawroz et al., 1994; van der Reit et al., 1994) .
To date only two global analyses of the whole genome have been undertaken with the view to determine the fractional allele loss (FAL) of specific tumours and thus provide information concerning the 'genetic burden' of the disease during its progression as measured by clinicopathological parameters and survival data. This type of analysis has been undertaken in colorectal (Vogelstein et al., 1989) and bladder cancers (Knowles et al., 1994) , and provides an indication of interacting genetic mechanisms in the development of these diseases. In addition, the results of such detailed allelotypes may aid the interpretation of carcinogenesis and the development of molecular progression models for specific tumours.
We have undertaken a very comprehensive allelotype of SCCHN using 145 microsatellite markers in order to identify common regions of allelic imbalance and to analyse the interactions of these regions by calculating the fractional allele loss (FAL) in these tumours. 
Materias and methods

Specimens
Results
A total of 80 SCCHN tumours were investigated for LOH, using 145 microsatellite markers and loss on individual chromosome arms was calculated using the total data set (Table IL) . A total of 1092 chromosomal arms were analysed, of which 956 (88%) were informative. The most frequent losses were found on chromosome arms 3p, 9p, 17p and 18q.
with over 450/o LOH; losses on lp, lq, 2p, 5q, 6p, 6q, 8p, 8q, 9q, llq, 13q, 17q and 19q were found in more than 20% of cancers ( Figure 2 ).
Loss of heterozygosity at specific loci
The highest incidence of LOH was found on chromosome 9p (24/39) with a 62% loss and this allelic imbalance was especially concentrated between the D9S161 (9p21) and D9S156 (9p23-9p22) informative markers in this region (JK Field et al., in preparation), which agrees with the observations of van der Riet et al. (1994) .
The second highest percentage of allelic imbalance (52%) was found on chromosome arm 3p from 61 informative tumours. Using 18 markers we found the greatest loss in the 3p24-p25 and 3pl3 regions and a very small incidence of LOH at the 3p2l site, including the D3SJ217 marker (3p2l) which had a LOH of only 10% JK Field et al., unpublished) .
Chromosome 17p revealed an LOH of 50% with the highest loss at the CHRNBI locus (17pl2-pll.l). Furthermore, as previously reported by Adamson et al. (1994) , LOH at this locus was found in 77% of the hypopharyngeal carcinomas studied.
Markers on 18q showed an overall LOH of 49% (20 41). however the main area of loss was not associated with the DCC marker at 18q21.1 but was found at D18S35 (18q21.l-q21.3) (33%) (Rowley et al., 1995) .
Significant losses, 29% (13 45). were also found on chromosome arm 5q. eight markers were used, including D5S346 (5q21 -q22) in the APC MCC region which showed 35% LOH (9 26). Six patients in this group of tumours showed loss only in this region. which was bounded in each case by informative heterozygous markers centromeric and telomenrc of D5S346. thereby indicating that this region plays an important role in some SCCHN.
LOH on 8p has been demonstrated in a range of tumours with the 8p2l.3-pll.22 region being of most interest. Our investigations using five microsatellite markers on 8p have shown 35% (14 40) LOH, which appears to be concentrated particularly at the D8S87 (8pl2) and ANKI (8p2l.1-pll.2) loci (29% and 20% LOH respectively). However, when the results of these two markers were combined. 37% (13 35) LOH was demonstrated (Kiaris et al., 1994) .
LOH has also been observed on chromosome arm lp in a range of tumours. with the lp3l.2-p21.3 region indicating that this may be a further target region in SCCHN. The cumulative loss of two markers in this region, DIS.159 (lp22.1-p21) and DIS167 (lp22-p21). was 24% (14,46).
Chromosome 11 contains an amplicon region at 11q13 which includes the int-2. cvclin D and EMS-I genes. We have found 23% LOH (9 39) on the 1llq arm and LOH at the int-2 locus was 17% (3 18).
In this data set, whole chromosome loss was seen only on chromosome 17 and in four tumours: 78. 192, 225 and 335 (11 % of cases). All of these chromosome arms showing LOH at greater than 20% (3p. 17p. 9p, 18q, Sq, 8p, lp and 1 Icq) have been previously shown to contain either known or putative tumour-suppressor genes. However, there are other arms in this study with greater than 20% LOH (lq, 2p, 6p, 6q, 8q. 13q. 17q and 19q) and these may also be target regions involved in the development of SCCHN.
LOH data analvsed against a range of clinicopathological parameters LOH data for each chromosomal arm were analysed against a range of clinicopathological parameters, including site of the tumour, histology, TNM staging, nodes at pathology and survival (Table I) . These calculations were undertaken on the whole data set of 80 tumours (previously untreated and previously treated) and on the two subgroups separately. In the whole data set (80 SCCHN), correlations were found between nodes at pathology and LOH on 9q (P = 0.020) and between histopathological grading and LOH on 12q (P = 0.022) and on 13q (P = 0.012). In the group of previously untreated tumours, a correlation was found between site and LOH on 3p (P = 0.032) and 8p (P= 0.029), while TNM staging correlated with LOH on 3p (P = 0.019) and 17p (P = 0.016). Only one association was found in the group of previously treated patients, between nodes at pathology and LOH on lIp (P = 0.045) (Table III) .
Fractional allele loss LOH data from all 39 chromosome arms were assessed separately for the 52 SCCHN tumours which had inform- (Table V) .
The FAL data was also investigated for a possible association with clinical outcome using the log-rank analysis. It was found that a FAL >median value correlated with poor survival (P < 0.032), and furthermore that a FAL > median value also correlated with a poor survival in the previously untreated patients (P<0.019) when analysed separately. In order to analyse a homogeneous group of patients for FAL with clinical outcome, we calculated the log rank on the subset of 40 advanced tumours (TNM III and IV) and this also demonstrated a correlation between FAL and prognosis (P < 0.05).
D6cuson
In this detailed allelotype of SCCHN we have demonstrated a complex set of genetic alterations, a finding that has also been described in a range of human cancers (Vogelstein et al., 1989; Sato et al., 1990 Sato et al., , 1991 Fujimori et al., 1991; Monrta et al., 1991; Tsuchiya et al., 1992; Yamaguchi et al., 1992; Aoki et al., 1994; Fujino et al., 1994; Knowles et al., 1994) . The highest LOH was found on the chromosome arms 3p, 9p, 17p and 18q which is in general agreement with previous studies on SCCHN (Ah-See et al., 1994; . Ah-See et al. (1994) .
target regions in SCCHN containing putative tumoursuppressor genes on 3p and 9p as well as a high LOH associated with the p53 gene. In addition, this analysis provides evidence for regions of minimal loss in SCCHN on lp, 8p, 17p and 18q (Adamson et al., 1994; Kiaris et al., 1994; Rowley et al., 1995; K Taylor et al., in preparation) . The lp minimal area of loss has been located at lp3l.2-p2l.3, a region previously shown by karyotype analysis to contain cytogenetic abnormalities (Jin et al., 1990 (Jin et al., , 1993 Owens et al., 1992) . A minimal area of loss has also been identified on 8p between 8pl2 and 8p21.2-p II in this series of tumours, a region considered to contain a candidate tumour-suppressor gene in colonic and hepatocellular carcinomas (Fujiwara et al., 1993; Cunningham et al., 1994) . We have recently described a novel region on 17p distinct from TP53, at CHRNBI (17q12-pl 1.1), in SCCHN which has a particularly high loss in hypopharyngeal carcinomas (77%) (Adamson et al., 1994) . Furthermore the detailed analysis of 18q has allowed us to identify a region at 18q21.1-q21.3 as a target region in SCCHN, which does not appear to be the DCC (deleted in colon cancer) gene as we found a very low LOH at the DCC locus. Thus it may be argued that there is a second tumour-suppressor gene in this region on 18q that is involved in SCCHN.
Two further chromosomal regions considered to contain tumour-suppressor genes in other neoplasms have not been shown to play an important role in SCCHN. Even though there is frequent LOH on 13q (Yoo et al., 1994) there does not appear to be inactivation of the retinoblastoma gene, and it has been argued by these authors that there may be another tumour-suppressor locus at 13ql4. Also, the APC/ MCC locus on 5q, which has been demonstrated to be involved in colorectal carcinomas (Kinzler et al., 1991) and has previously been shown to have a high LOH in SCCHN (Ah-See et al., 1994) , may not in fact be the target locus, as mutations in the APC gene have rarely been found in oral cancers (Uzawa et al., 1994) .
Analysis of LOH for each chromosomal arm was assessed against a range of clinicopathological parameters (Table III) . In particular, a correlation was found between site and LOH on 3p and 8p, while TNM staging correlated with LOH on 3p and 17p in previously untreated tumours. Also, in the group of previously untreated and previously treated tumours a correlation was found between LOH on 9q and positive nodes at pathology, and histological grading correlated with LOH on 12q and 13q. In a detailed study undertaken by Lee et al. (1994) , on chromosome 13 (using 13 markers), a correlation was found between LOH on 13q and lymph node metastasis. Moreover, these authors reported that they found similar LOH in a subset of the tumours in the adjacent non-malignant mucosa. However, no correlation between LOH at 13q and lymph node metastasis was observed in the study described here.
The phenomenon of microsatellite instability (MI) (Mao et al., 1994; Field et al., 1995) has been demonstrated in some of these SCCHN tumours, but no correlation was found between MI and LOH on any chromosome arm in this study. MI is therefore considered to be a separate pathogenic mechanism in the development of SCCHN.
The fractional allele loss (FAL) data were assessed for 52 tumours on which there was LOH information on nine or more chromosome arms. In this group we found a median FAL value of 0.22, mean of 0.25 (range 0.0-0.80). This demonstrates that alleles were lost on average from 25% of the chromosome arms in these tumours; a figure that is comparable with that obtained in non-small-cell carcinoma and colorectal carcinomas (0.2), bladder and breast carcinomas (0.11) and osteosarcarcinomas (0.32) (Sato et al., 1990 (Sato et al., , 1991 Morita et al., 1991; Tsuchiya et al., 1992; Knowles et al., 1994 (Field et al., 1991 Field, 1992; Brennan et al., 1995) , but no correlation has been found between these carcinogens and FAL in this analysis. In colorectal carcinomas, Vogelstein et al. (1989) We have demonstrated that a FAL>median value correlated with a poor prognosis in all 52 patients analysed (P<0.032) and also in the subset of previously untreated patients (P<0.019) calculated by the log-rank method. Vogelstein et al. (1989) also showed a relationship between FAL and prognosis for colon cancers with a similar number and distribution of patients (P <0.01) using Fisher's exact test. Thus the argument originally proposed by Vogelstein et al. (1989) that recognition of accumulated genetic damage, as provided by the allelotype, provides a useful molecular indicator of the tumour behaviour is supported by the findings of this study.
